Literature DB >> 33439305

Venetoclax-induced panniculitis in an acute myeloid leukemia patient.

Po-Wei Liao1, Ren Ching Wang2,3, Tsung-Chih Chen1,4, Chieh-Lin Jerry Teng5,6,7.   

Abstract

Entities:  

Year:  2021        PMID： 33439305     DOI： 10.1007/s00277-020-04372-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  6 in total

1.  Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than Polychemotherapy.

Authors:  David Michonneau; Tony Petrella; Nicolas Ortonne; Saskia Ingen-Housz-Oro; Nathalie Franck; Stéphane Barete; Maxime Battistella; Marie Beylot-Barry; Béatrice Vergier; Marc Maynadié; Christine Bodemer; Olivier Hermine; Martine Bagot; Nicole Brousse; Sylvie Fraitag
Journal:  Acta Derm Venereol       Date:  2017-03-10       Impact factor: 4.437

2.  Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.

Authors:  Courtney D DiNardo; Keith W Pratz; Anthony Letai; Brian A Jonas; Andrew H Wei; Michael Thirman; Martha Arellano; Mark G Frattini; Hagop Kantarjian; Relja Popovic; Brenda Chyla; Tu Xu; Martin Dunbar; Suresh K Agarwal; Rod Humerickhouse; Mack Mabry; Jalaja Potluri; Marina Konopleva; Daniel A Pollyea
Journal:  Lancet Oncol       Date:  2018-01-12       Impact factor: 41.316

3.  Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Authors:  Matthew S Davids; Michael Hallek; William Wierda; Andrew W Roberts; Stephan Stilgenbauer; Jeffrey A Jones; John F Gerecitano; Su Young Kim; Jalaja Potluri; Todd Busman; Andrea Best; Maria E Verdugo; Elisa Cerri; Monali Desai; Peter Hillmen; John F Seymour
Journal:  Clin Cancer Res       Date:  2018-06-12       Impact factor: 12.531

4.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

Authors:  Courtney D DiNardo; Brian A Jonas; Vinod Pullarkat; Michael J Thirman; Jacqueline S Garcia; Andrew H Wei; Marina Konopleva; Hartmut Döhner; Anthony Letai; Pierre Fenaux; Elizabeth Koller; Violaine Havelange; Brian Leber; Jordi Esteve; Jianxiang Wang; Vlatko Pejsa; Roman Hájek; Kimmo Porkka; Árpád Illés; David Lavie; Roberto M Lemoli; Kazuhito Yamamoto; Sung-Soo Yoon; Jun-Ho Jang; Su-Peng Yeh; Mehmet Turgut; Wan-Jen Hong; Ying Zhou; Jalaja Potluri; Keith W Pratz
Journal:  N Engl J Med       Date:  2020-08-13       Impact factor: 91.245

5.  Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.

Authors:  Andrew H Wei; Pau Montesinos; Vladimir Ivanov; Courtney D DiNardo; Jan Novak; Kamel Laribi; Inho Kim; Don A Stevens; Walter Fiedler; Maria Pagoni; Olga Samoilova; Yu Hu; Achilles Anagnostopoulos; Julie Bergeron; Jing-Zhou Hou; Vidhya Murthy; Takahiro Yamauchi; Andrew McDonald; Brenda Chyla; Sathej Gopalakrishnan; Qi Jiang; Wellington Mendes; John Hayslip; Panayiotis Panayiotidis
Journal:  Blood       Date:  2020-06-11       Impact factor: 22.113

6.  Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.

Authors:  Amir T Fathi; Courtney D DiNardo; Irina Kline; Laurie Kenvin; Ira Gupta; Eyal C Attar; Eytan M Stein; Stephane de Botton
Journal:  JAMA Oncol       Date:  2018-08-01       Impact factor: 33.006
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.